Pancreatic Cancer Research

ResearcherJinan Central HospitalActive in the last 2 years

Zhao Liu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2058-1562; OpenAlex author ID A5100686089. Sources: OpenAlex.

Their work

Papers
12 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 4 papers · 2024: 1 paper · 2025: none · 2026: 1 paper

Papers 12

  1. High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Cancer Resection. First author DOI 10.1002/jhbp.70032↗
  2. Prognostic impact of tumor marker kinetics and normalization during neoadjuvant chemotherapy for pancreatic cancer. First author DOI 10.21037/hbsn-23-662↗
  3. Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis… Co-author DOI 10.1038/s41416-022-02106-9↗
  4. The Prognostic Role of Serine Racemase in Patients With Pancreatic Cancer: A New Marker in Cancer Metabolism. Co-author DOI 10.1097/mpa.0000000000002210↗
  5. Biological and Clinical Impacts of Glucose Metabolism in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15020498↗
  6. Statins exert anti-growth effects by suppressing YAP/TAZ expressions via JNK signal activation and eliminate the immune suppression by downregulating PD-L1 exp… Co-author PMID 37293171↗
  7. Thrombospondin-1 overexpression stimulates loss of Smad4 and accelerates malignant behavior via TGF-β signal activation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2022.101533↗
  8. High Expression of Bloom Syndrome Helicase is a Key Factor for Poor Prognosis and Advanced Malignancy in Patients with Pancreatic Cancer: A Retrospective Study. Co-author DOI 10.1245/s10434-022-11500-9↗
  9. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.700315↗
  10. Recent advances in artificial intelligence for pancreatic ductal adenocarcinoma. Co-author DOI 10.3748/wjg.v27.i43.7480↗
  11. Prognostic Impact of Coagulation Activity in Patients Undergoing Curative Resection for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/invivo.12111↗
  12. The MRTF-A/B function as oncogenes in pancreatic cancer. First author DOI 10.3892/or.2015.4329↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromitsu Hayashi · 11 shared papers, 2020–2026 · strength 1.91
  2. Norio Uemura · 7 shared papers, 2020–2023 · strength 1.04
  3. Kosuke Mima · 6 shared papers, 2022–2026 · strength 1.04
  4. Hideo Baba · 5 shared papers, 2020–2024 · strength 0.84
  5. Hiroki Sato · 5 shared papers, 2021–2023 · strength 0.80
  6. Shigeki Nakagawa · 5 shared papers, 2022–2023 · strength 0.76
  7. Kazuki Matsumura · 5 shared papers, 2020–2023 · strength 0.70
  8. Katsunori Imai · 5 shared papers, 2020–2023 · strength 0.70
  9. Takayoshi Kaida · 3 shared papers, 2022–2023 · strength 0.44
  10. Takashi Matsumoto · 2 shared papers, 2022–2026 · strength 0.42
  11. Tatsunori Miyata · 2 shared papers, 2023 · strength 0.32
  12. Chuan Lan · 2 shared papers, 2022–2023 · strength 0.31
  13. Hideo Baba · 2 shared papers, 2022–2023 · strength 0.30
  14. Yuki Kitano · 1 shared paper, 2026 · strength 0.28
  15. Toru Takematsu · 1 shared paper, 2026 · strength 0.28
  16. Hirohisa Okabe · 1 shared paper, 2026 · strength 0.28
  17. Shinsei Yumoto · 1 shared paper, 2026 · strength 0.28
  18. Masaaki Iwatsuki · 1 shared paper, 2026 · strength 0.28
  19. Fumimasa Kitamura · 2 shared papers, 2020–2022 · strength 0.23
  20. Hideo Baba · 1 shared paper, 2023 · strength 0.20
  21. Masayo Tsukamoto · 1 shared paper, 2023 · strength 0.17
  22. Hidetoshi Nitta · 1 shared paper, 2023 · strength 0.16
  23. Hideo Andreas Baba · 1 shared paper, 2021 · strength 0.15
  24. Hideo Baba · 1 shared paper, 2021 · strength 0.14
  25. Rumi Itoyama · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.